Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02932150 · ClinicalTrials.gov registry record · Phase 2
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
A Phase 2 study of Chronic Hepatitis B, sponsored by Gilead Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT02932150: Recruiting Phase 2 study of Chronic Hepatitis B, sponsored by Gilead Sciences.
NCT02932150 is a Phase 2 study of Chronic Hepatitis B that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 150 participants, below the 283-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02932150, a Phase 2 study of Chronic Hepatitis B, is actively recruiting participants, sponsored by Gilead Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TAF
Study Locations (20)
Texas
- Children's Medical Center - Dallas
- Cook Children's Medical Center - Fort Worth
- Texas Children's Hospital - Main Hospital - Houston
- American Research Corporation at Texas Liver Institute - San Antonio
California
- Children's Hospital of Los Angeles - Los Angeles
- Rady Childrens Hospital - San Diego
- University of California, San Francisco (UCSF) - San Francisco
Florida
- University of Miami/Schiff Center for Liver Diseases - Miami
- AdventHealth Medical Group - Orlando
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Colorado
- Children's Hospital Colorado - Aurora
Georgia
- Children's Healthcare of Atlanta - Atlanta
Indiana
- Indiana University School of Medicine - Indianapolis
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2016-11 |
| Est. Completion | 2029-10 |
| Phase | Phase 2 |
What NCT02932150 shows while recruiting
NCT02932150 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 283-participant average among 14 other Chronic Hepatitis B trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Chronic Hepatitis B appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02932150 names 20 study sites across 13 states, led by Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02932150 about?
NCT02932150 is a clinical study titled "Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection". The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.
What is the current status of trial NCT02932150?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2016-11. Estimated completion is 2029-10.
What conditions does trial NCT02932150 study?
This clinical trial studies the following conditions: Chronic Hepatitis B.
What interventions are being tested in trial NCT02932150?
The interventions under investigation include: Placebo (DRUG), TAF (DRUG).
Who is sponsoring clinical trial NCT02932150?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02932150 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02932150's enrollment target sits among peer trials
150 8th of 14 higher than 7 of 14 other Chronic Hepatitis B trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Hepatitis B trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
RECRUITING · Phase 2
-
Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B
RECRUITING · Phase 2
-
Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment
COMPLETED · Phase 2
-
Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment
COMPLETED · Phase 2
-
Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants
COMPLETED · Phase 2
-
Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia